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Abstract
BACKGROUND
Non-alcoholic fatty liver disease (NAFLD) dominates the landscape of modern
hepatology. Affecting 25% of the general population, there is critical unmet need
to identify broadly available, safe and cost-effective treatments. Cumulative
evidence in animal and human models suggests that intrahepatic and skeletal
muscle fatty acid oxidation is impaired in NAFLD, such that lipid accretion is not
matched by efficient utilisation. L-carnitine is a crucial mediator of fatty acid
metabolism in vivo, promoting mitochondrial lipid β-oxidation and enhancing
tissue metabolic flexibility. These physiological properties have generated
research interest in L-carnitine as a potentially effective adjunctive therapy in
NAFLD.
AIM
To systematically review randomised trials reporting effects of dietary L-carnitine
supplementation on liver biochemistry, liver fat and insulin sensitivity in
NAFLD.
METHODS
Search strategies, eligibility criteria and analytic methods were specified a priori
(PROSPERO reference: CRD42018107063). Ovid MEDLINE, Ovid EMBASE,
PubMed, Web of Science and the Cochrane Library were searched from their
inception until April 2019. Outcome measures included serum concentrations of
alanine and aspartate aminotransferase (ALT and AST), liver fat and insulin
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sensitivity assessed by the homeostasis model of insulin resistance (HOMA-IR).
A random effects meta-analysis was performed for, ALT, AST and HOMA-IR
measures separately. Between-study heterogeneity was measured using I2
statistics.
RESULTS
Five eligible randomised trials were included in the qualitative and quantitative
synthesis (n = 338). All of the 5 included trials assessed the effect of L-carnitine on
serum ALT, identified from Italy, South Korea and Iran. Weighted mean
difference (WMD) for ALT between L-carnitine and control groups after
intervention was -25.34 IU/L [95%CI: -41.74-(-8.94); P = 0.002]. WMD for AST
between L-carnitine and control groups was -13.68 IU/L (95%CI: -28.26-0.89; P =
0.066). In three studies (n = 204), HOMA-IR was evaluated. WMD for HOMA-IR
between L-carnitine and control groups was -0.74 units [95%CI: -1.02-(-0.46); P <
0.001]. Two studies using validated outcome measures reported a significant
reduction in liver fat in L-carnitine vs control groups post-intervention (P <
0.001).
CONCLUSION
Pooled results indicate that L-carnitine supplementation attenuates ALT, liver fat
and insulin resistance in NAFLD cohorts, confirming a beneficial effect of L-
carnitine for a highly prevalent condition with a growing economic burden.
Key words: L-Carnitine; Non-alcoholic fatty liver disease; Nonalcoholic steatohepatitis;
Liver function; Insulin resistance; Meta-analysis; Systematic Review
©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
Core Tip: Non-alcoholic fatty liver disease (NAFLD) presents a major public health
challenge. As a leading cause of abnormal liver chemistry, rising in prevalence together
with obesity and insulin resistance, there is critical unmet need to identify cost-effective,
population-based treatment. We synthesised evidence from randomised trials published
to date evaluating the effect of dietary L-carnitine supplementation on transaminases,
liver fat and insulin resistance in NAFLD. We demonstrate a significant reduction in
serum alanine aminotransferase, homeostasis model of insulin resistance and liver fat
with dietary L-carnitine supplementation. L-carnitine could therefore present a novel
therapeutic tool for NAFLD and its metabolic associations.
Citation: Thiagarajan P, Chalmers J, Ban L, Grindlay D, Aithal GP. L-carnitine
supplementation in non-alcoholic fatty liver disease: A systematic review and meta-analysis.
World J Meta-Anal 2020; 8(1): 4-14
URL: https://www.wjgnet.com/2308-3840/full/v8/i1/4.htm
DOI: https://dx.doi.org/10.13105/wjma.v8.i1.4
INTRODUCTION
Non-alcoholic fatty liver disease (NAFLD) has rapidly emerged as a leading cause of
chronic liver disease and liver transplantation worldwide[1]. The global prevalence of
NAFLD is  estimated to  be 25.24%[2],  rising to  66% and 90% in those with type 2
diabetes  and  obesity,  respectively[3].  Although  progression  to  non-alcoholic
steatohepatitis (NASH) is limited to approximately 30% of individuals with NAFLD,
the high population prevalence of NAFLD heralds a looming socioeconomic burden
due to the consequences of its progression, including end-stage liver disease[4]. In EU4
countries alone (France, Germany, Italy, United Kingdom), the annual cost associated
with NAFLD is estimated to be €35 billion[5]. Diet and lifestyle modification remain
current  standard of  care,  and there is  no specifically licensed disease-modifying
therapy available.
L-Carnitine is a naturally occurring water-soluble quaternary amine which acts as a
crucial  mediator  of  fatty  acid  metabolism in  vivo.  The  role  of  carnitine  as  a  key
regulator of intracellular bioenergetics has gained traction in the search for broadly
applicable treatments for metabolic disorders, including obesity and type 2 diabetes.
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The ability of L-carnitine to regulate muscle mitochondrial fuel selection, through
promoting both lipid oxidation and non-oxidative glucose disposal, renders it an
attractive target for therapeutic intervention in the context of insulin resistance[6].
Cumulative evidence in both animal and human models suggests that intrahepatic
and skeletal muscle fatty acid transport and oxidation is impaired in NAFLD and
insulin resistance,  such that  excessive lipid accretion is  not  matched by efficient
utilisation[7,8]. Thus, the effect of carnitine supplementation in the context of NAFLD
specifically has been the focus of recent interest. This review aims to critically and
systematically  evaluate  all  human  randomised  trials  investigating  the  effect  of
carnitine on liver fat and/or metabolic parameters in NAFLD.
MATERIALS AND METHODS
Search strategies, eligibility criteria and analytic methods were specified a priori in the
study protocol,  which was  registered with  the  PROSPERO database  (CRD42018
107063).
Search strategy
We performed a systematic  literature search for  randomised trials  reporting the
effects of dietary L-carnitine supplementation on liver biochemistry and liver fat in
adult individuals with NAFLD and NASH.
The databases searched were PubMed, Ovid EMBASE, Ovid MEDLINE, Web of
Science Core Collection and the Cochrane Library. The full search strategy used in
Ovid MEDLINE is provided in Appendix 1.  Databases were searched from their
inception until April 2019. No language restrictions were used. For each database, a
comprehensive list of alternative terms for NAFLD were combined with alternative
terms for L-carnitine, using the Boolean operator AND. Reference lists of studies
ultimately selected for inclusion were searched to identify any other relevant research.
Diagnostic criteria for NAFLD varied significantly between studies, but eligible
studies included adult individuals diagnosed with NAFLD on the basis of validated
histological, imaging or biochemical tests, including the following, and where other
causes  of  hepatic  steatosis  had been excluded:  (1)  Liver  histology;  (2)  Magnetic
Resonance Imaging with proton density fat fraction (MRI-PDFF) or proton magnetic
resonance spectroscopy (1H-MRS); (3) Computed Tomography (CT); (4) Ultrasound
and  (5)  Serum  concentrations  of  alanine  aminotransferase  (ALT)  and  aspartate
aminotransferase (AST) in conjunction with impaired glucose tolerance and in the
absence of documented alcohol excess.
Primary outcome measures included change in serum concentrations of ALT, AST
and  liver  fat  (as  assessed  either  by  liver  biopsy,  cross-sectional  imaging  or
ultrasound). Secondary outcome measures included changes in insulin sensitivity
parameters  (as  assessed  by  the  HOMA-IR)  and,  where  available,  markers  of
inflammation and oxidative stress.
Study selection was performed independently by two separate reviewers (PT and
JC) with any disagreements revolved by a third researcher (GPA). Titles and abstracts
of  returned  searches  were  evaluated  against  eligibility  criteria.  Those  meeting
eligibility criteria based on title and abstract were subsequently read in full. Wherever
journal articles were found to contain insufficient information for critical analysis,
attempts were made to contact the authors directly for clarification of missing details.
Eligibility criteria
Eligible published studies included human randomised trials evaluating the effect of
carnitine  supplementation  on  liver  fat,  liver  enzymes,  glucose  and  markers  of
inflammation or oxidative stress in adult individuals with NAFLD. Only full reports
were considered as eligible for inclusion on the basis that they provided sufficient
data to permit critical analysis. Studies were considered eligible for inclusion if they:
(1) Were randomised in design; (2) Evaluated L-carnitine versus placebo, L-carnitine
plus another intervention versus that intervention alone, or L-carnitine versus no
intervention;  (3)  Included a  patient  population  diagnosed with  NAFLD and/or
NASH based on validated histological, radiological or biochemical parameters as
listed above; and (4) Included only subjects aged 18 years or above. Studies were
excluded if they: (1) Were non-randomised in design e.g., case reports, reviews or
observational studies; (2) Included patients with another cause of hepatic steatosis e.g.,
alcohol,  genetic  or  viral  liver  disease;  (3)  Were  animal  studies;  and  (4)  Did  not
evaluate outcomes of interest as detailed above.
There  were  no  restrictions  based  on  dosage,  formulation  or  frequency  of
administration.  Interventions  in  the  control  group  included  active  placebo
supplementation,  hypocaloric  diet  and metformin  therapy.  Trials  evaluating  L-
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carnitine supplementation together with other interventions,  in the absence of  a
control group consisting of the other interventions alone, were excluded. No specific
treatment duration was specified for inclusion in this review.
Data extraction and quality assessment
Data extracted from individual studies included (1) participant demographics; (2)
intervention  type  and  dose;  (3)  method  of  NAFLD  diagnosis;  (4)  outcome
measurements of  liver fat,  liver enzymes,  glycometabolic  profile  and markers of
inflammation and oxidative stress; (5) documentation as to whether informed consent
was gained; (6) methods of randomisation; (7) allocation concealment; (8) participant
and staff blinding; (9) blinding of outcome assessment; (10) presence of incomplete
outcome data; and (11) evidence of any selective reporting. The Cochrane risk of bias
tool[9]  was then used to  systematically  appraise  each included study in  terms of
methodological  quality  and  validity  according  to  the  criteria  of  the  Cochrane
guidelines.
Statistical analysis
A  random  effects  meta-analysis  was  performed  for  ALT,  AST  and  HOMA-IR
measures separately. Weighted mean difference (WMD) with 95%CI were calculated.
Between-study  heterogeneity  was  measured  using  I2  statistics,  with  I2  >  50%
indicating significant heterogeneity. The analysis was performed using Stata software
version 11.0  Stata  (Version 11.2,  StataCorp,  College Station,  Texas).  Resultswere
summarised using Forest plots.
RESULTS
Search results
Figure 1 depicts the PRISMA flowchart process of identification and selection of
eligible studies for inclusion in the qualitative and quantitative syntheses. Primary
database searches yielded 883 citations. After de-duplication, 692 remaining citations
were  screened for  eligibility  by reading titles  and abstracts.  Of  these  remaining
studies, 675 were excluded. Of the remaining 17 citations, full text articles retrieved
were read in full to determine eligibility. Twelve studies were subsequently excluded.
Table 1 summarises study characteristics for the five randomised trials ultimately
included  in  the  qualitative  and  quantitative  synthesis[10-14].  In  total,  these  trials
comprised 338 patients (234 men, 104 women). In 3 trials, non-diabetic patients with
NAFLD were  recruited  and  the  other  2  trials  recruited  individuals  with  type  2
diabetes mellitus and NAFLD.
Quality of included studies
Methodological quality was assessed using criteria set out in the Cochrane Handbook
for Systematic Reviews (Figure 2). All trials described randomising participants to L-
carnitine and control arms. However,  only two of the five trials[10,11]  reported the
methods used to generate random allocation sequence (i.e., computer generated tool)
to a standard sufficient enough to be judged as having a low risk of bias. In the other 3
trials, no information was provided regarding methods of blinding and insufficient
information was provided to enable informed decision-making regarding adequacy of
randomisation.  One  trial  reported  randomising  participants  by  using  random
numbers allocated to consecutive patients; this was considered to confer a high risk of
selection bias[12].
Regarding allocation concealment, only two studies[10,11] reported efforts to conceal
allocation sequences from personnel as well as patients. In two of the studies, genuine
blinding was considered impossible due to lack of a placebo arm[13,14]. In the remaining
two trials, insufficient information was given to determine whether a robust allocation
concealment  process  was  undertaken.  Three  of  the  five  studies  accounted  for
incomplete  outcome  data  and  clearly  explained  any  loss  to  follow  up  and
exclusions[10,11,13]. The other two studies lacked explanations for trial exclusion.
Selective reporting was considered to be present in two out of the five included
studies. Alavinejad et al[12] (2016) with sonographic grade of liver fat as an outcome
measure in their study, noted that “follow up ultrasonography did not show any
significant change in comparison with baseline reports”. However no baseline or post-
intervention values were reported. Somi et al[14] (2014) reported changes from baseline
in sonographically-determined grade of NAFLD in patients in the L-carnitine arm of
the study, with nine of the L-carnitine treated patients having no evidence of NAFLD
on post-intervention ultrasound. However it was unclear how many patients had
progressed or regressed in steatosis grade.
In  three  out  of  the  five  trials,  funding sources  and conflicts  of  interests  were
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Figure 1
Figure 1  PRISMA flow diagram.
explicitly stated, whereas in the other two trials no mention was made of either[12,14].
Efficacy,  safety  and  compliance  measures  were  reported  in  3  studies  but  no
description of methods to evaluate compliance was made in the other two studies and
Somi et al[12,14]  (2014) did not report any safety visits for subjects during 24 wk of
supplementation. Statistical analyses were reported in all five trials.
Outcomes
Estimates  were  made  on  the  effect  of  L-carnitine  on  outcomes  including  liver
transaminases, the HOMA-IR and liver fat (where measured).
ALT:  All of the five included trials were for meta-analysis of ALT measures after
intervention (Figure 3). The WMD for ALT between the L-carnitine groups and the
control groups after intervention was -25.34 IU/L [95%CI: -41.74-(-8.94), P = 0.002]
(Figure 3). The I2 was 95.8%, indicating statistically significant heterogeneity between
the studies.
AST:  All  five  trials  were  included  for  meta-analysis  of  AST  measures  after
intervention. The WMD for AST between the L-carnitine group and the control group
after intervention was -13.68 IU/L (95%CI: -28.26-0.89) (P = 0.066) (Figure 4). The I2
was 93.4%, indicating high statistical heterogeneity between the studies.
Liver fat:  Four of the included studies evaluated hepatic steatosis at baseline and
post-intervention. Outcome measures differed between the studies, precluding the
possibility of a quantitative synthesis of results. In two studies, ultrasonography was
used to grade liver fat at baseline and post-intervention[12,14]. In another study, CT
imaging was used[11] and in the fourth study, liver fat was evaluated histologically[10].
Malaguarnera et al[10]  (2010) assessed liver fat using paired biopsies;  the group
reported a significant reduction in steatosis in the group randomised to L-carnitine
compared to placebo (1.68 ± 0.76 vs 0.94 ± 0.88; P < 0.001). However, within-group
analysis also demonstrated that steatosis reduction was significant in the placebo
group (hypocaloric diet + placebo) compared to baseline values (P < 0.001). In the
same study,  other histological  features of  NASH were shown to be significantly
attenuated following 24 wk of L-carnitine therapy compared to placebo, including
parenchymal inflammation (P < 0.001), hepatocellular injury (P < 0.05) and fibrosis (P
< 0.05).  However,  it  is  again  worth  noting  that  within-group comparisons  with
baseline values also determined a significant reduction in these parameters following
placebo supplementation.
Another study used hepatic CT with liver attenuation index (LAI) to evaluate
steatosis  before  and after  the  study[11].  Authors  reported  that  the  patient  group
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Table 1  Published studies to date evaluating the effect of L-carnitine supplementation on liver fat and/or biochemistry in non-alocholic
fatty liver disease
Ref.
Study
population
(diagnosis);
comorbi-
dities
Sample size
(M/F)
Control/
Carnitine
Age (yr) BMI Duration(wk)
Intervention
(dose)
Outcome
Measures Control Results
Malaguar-
nera et al[10]
Biopsy-
proven
NASH
without
diabetes
74 (40/34) 47.8 ± 5.8
(CTRL)
26.5 ± 3.8
(CTRL)
24 L-carnitine
(1000 mg BD)
plus
hypocaloric
(1600 cal ) diet
Primary:
Improvement
in histological
features of
NASH
Placebo plus
Hypocaloric
(1600 cal) diet
Primary
Outcome: ↓
NASH
activity score1
(9.42-3.19),
↓ALT1 ↓AST1,
↓GGT1 ↓TC1,
↓LDL1,
↑HDL1,
↓GLC1,
↓HOMA-IR1,
↓CRP1,
↓TNFα1
38 (CTRL) 47.9 ± 5.4
(CAR)
26.6 ± 3.7
(CAR)
Other: ALT,
AST, lipid
profile, GLC,
HOMA-IR,
CRP, TNFα
36 (CAR)
Bae et al[11] NAFLD with
type 2
diabetes
78 (54/24) 52 ± 9.4
(CTRL)
26.7 ± 3.7
(CTRL)
12 Carnitine
orotate
complex (824
mg TDS)
Primary:
Change in
ALT
Placebo Primary
outcome:
↓ALT (89.7%
vs 17.9%)1
39 (CTRL) 50.6 ± 9.3
(CAR)
28.2 ± 2.6
(CAR)
Other: Liver
attenuation
index (CT)
Other: ↓Liver
attenuation
index1 (0.74 ±
8.05 vs 6.21 ±
8.96)1,
↓HbA1c,
↓GLC,
↓HOMA-IR2
39 (CAR)
Alavinejad et
al[12]
NAFLD
(ultrasound+
raised ALT)
with T2DM
54 (38/16) 59 ± 9 (CTRL) 29.5 ± 3.6
(CTRL)
12 L-carnitine
(750 mg TDS)
Primary: AST,
ALT
Placebo Primary
outcome:
↓ALT1, ↓AST1
Other: ↓TG2,
↓GLC2,
↓HbA1c2
26 (CTRL) 60 ± 5 (CAR) 28.6 ± 4.6
(CAR)
Other: TG,
GLC, HbA1c28 (CAR)
Hong et al[13] NAFLD
(plasma ALT
40-250) and
impaired
glucose
tolerance
(HbA1C ≥
6.0%)
52 (36/16) 52.0 ± 9.6
(CTRL)
27.0 ± 3.1
(CTRL)
12 Carnitine-
orotate
complex (300
mg TDS) +
metformin
Primary:
change from
baseline ALT
Metformin
alone
Primary
outcome: ↓
ALT1
26 (CTRL) 51.5 ± 9.4
(CAR)
27.2 ± 2.6
(CAR)
Other: GLC,
HbA1c, m t
DNA copy
number, urine
8-OHdG
Other:
↓HbA1c2, ↑
plasma
mtDNA copy
number1,
↓GLC2, ↓urine
8-OHdG
26 (CAR)
Somi et al[14] NAFLD
(ultrasound +
plasma ALT ≥
40)
80 (66/14) 40.7 ± 8 29.4 ± 3.9 24 L-carnitine
(250 mg BD)
Primary:
ALT, AST
No treatment Primary
outcome:
↓ALT1, ↓AST1
Other:
Sonographic
change in
liver fat, BMI
Other: ↓ liver
fat on USS
NASH: Nonalcoholic steatohepatitis; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; GLC: Glucose; HOMA-IR: Homeostasis model of
insulin resistance; CRP: C-reactive protein; TNFα: Tumour Necrosis Factor alpha; HbA1C: Haemoglobin A1C; T2DM: Type 2 diabetes mellitus; TG:
Triglyceride; mt DNA: Mitochondrial DNA; oHdg: 8-hydroxydeoxyguanosine.
1Denotes statistically significant results.
2Denotes non-statistically significant results.
receiving L-carnitine complex supplementation had a mean increase in LAI values of
6.21 ± 8.96 Hounsfield Units (HU) (P < 0.001), indicating significant reduction in liver
fat, whereas the placebo group showed no significant change (LAI increased by 0.74 ±
8.05  HU,  P  =  0.582).  The changes  in  LAI were  found to  correlate  inversely  with
changes in ALT.
Alavinejad et al[12] (2016) reported no significant difference between baseline and
post-intervention sonographic liver fat in either the L-carnitine or placebo groups in
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Figure 2
Figure 2  Methodological quality assessment according to the Cochrane risk of bias tool.
their study. However, absolute values were not provided in the published article.
Finally,  Somi  et  al[14]  (2014)  reported  a  significant  reduction  in  patients  with
sonographic grade 2 liver fat in the placebo but not the L-carnitine groups. In the L-
carnitine group, 9 patients with sonographic evidence of fatty liver at baseline had
resolution of fatty liver disease on post-intervention ultrasonography, suggesting a
beneficial effect of L-carnitine on liver fat; however, this was reported to be non-
significant.  Thus,  two high  quality  RCTs  utilising  histology  and cross-sectional
imaging for quantifying liver fat reported significant outcomes following L-carnitine
supplementation,  whereas  the  two  trials  utilising  ultrasonography  reported  no
significant difference in liver fat with L-carnitine.
HOMA-IR and glycometabolic profile: Three papers were included for meta-analysis
of HOMA-IR measures after intervention. The WMD for HOMA-IR between the L-
carnitine and control groups after intervention was -0.74 units [95%CI: -1.02-(-0.46)] (P
< 0.001) (Figure 5). The I2  was 0%, indicating statistical homogeneity between the
studies.
Adverse events:  Adverse events (AE) were reported in 3 studies included in this
review,  including  mild  headache,  musculoskeletal  pain  and  gastrointestinal
disturbance[10,11,13]. All AE rates were lower in the intervention versus placebo groups
and no serious adverse events were reported.
Inflammation and oxidative stress: Malaguarnera et al[10] (2010) reported a significant
reduction in hepatocellular injury (P < 0.05), parenchymal inflammation (P < 0.001),
plasma C-reactive protein (CRP) and tumour necrosis factor alpha (TNFα) (P < 0.001)
in L-carnitine treated patients compared to placebo. Hong et al[13] (2014) evaluated
inflammation and oxidative stress at baseline and post-intervention in using high-
sensitivity  CRP  (hs-CRP)  and  urine  8-hydroxy-2’-deoxyguanosine  (8OHdG),
respectively and report significant reduction in 8OHdG in the group treated with L-
carnitine (P = 0.034).
DISCUSSION
Summary of evidence
To our knowledge, this is the first reported systematic review to evaluate the effect of
dietary L-carnitine supplementation on liver fat, markers of liver injury and insulin
resistance profiles in NAFLD populations. Pooled results from five randomised trials
suggest that L-carnitine supplementation is associated with significant attenuation of
liver fat,  and reduction in serum ALT levels,  the most commonly used surrogate
biomarker of hepatocellular injury. A reduction in AST following L-carnitine therapy
was also seen, though this did not reach statistical significance. Our results further
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Figure 3
Figure 3  Meta-analysis of alanine aminotransferase measures after intervention.
suggest  that  L-carnitine  can  improve  insulin  sensitivity  in  NAFLD  cohorts,  as
measured indirectly  using the  HOMA-IR index.  These  outcomes are  potentially
important to clinical practice, as they confirm a beneficial effect of a broadly available
nutrient.
Strengths and limitations
This review comprised a robust and comprehensive database search with no language
restrictions. The search strategy was implemented by two reviewers separately, and
both authors agreed on papers selected for inclusion as well as reasons for exclusion.
Included studies were read and assessed for bias independently by each reviewer; any
disagreements  in the risk of  bias  tool  were referred to a  third reviewer for  final
arbitration. No publication bias was found to be present for selected outcomes entered
into the meta-analysis.
There were several  limitations associated with this  review.  Firstly,  despite  an
extensive literature search, only five randomised studies were available evaluating L-
carnitine on liver markers in NAFLD. Of these, only four evaluated change in liver fat
as an outcome measure. Despite another trial being published, we were unable to
obtain the full text after attempts to contact the authors of the paper.
Secondly,  poor  methodological  quality  was  inherent  in  three  of  the  included
studies. For example, while all studies claimed randomisation, only Malaguarnera et
al[10]  (2010) and Bae et  al[11]  (2015) described robust methods of  random sequence
generation. Lack of placebo control use in the studies conducted by Somi et al[13] (2014)
and Hong et al[14]  (2014) further reduced methodological quality and reliability of
reported results. Double-blind trial design is an important tool in minimising bias and
maximising reliability of research outcomes. In two of the included studies, there was
insufficient evidence to judge that robust blinding of participants and personnel
occurred. In the study conducted by Somi et al[14] (2014) no mention of blinding was
made. This led us to judge these studies as having as high risk of bias and thus further
reduced reliability of reported results.
There  was  heterogeneity  of  the  trials  with  respect  to  duration,  type  of  active
comparator drug and background therapy, as well as carnitine formulation and dose.
Two studies  used carnitine  in  complex with  orotic  acid  (carnitine-orotate);  thus
establishing a true effect of L-carnitine alone on outcomes measures was not possible.
Doses varied widely, from 500 mg daily to 2.25 grams daily, resulting in differential
exposure to active L-carnitine among patients in each individual study. The NAFLD
patient populations studied were also heterogenous, including patients both with and
without  diabetes,  patients  with  different  stages  of  NAFLD  and  geographical
differences  in  populations.  However,  all  5  studies  reported  reductions  in  ALT,
suggesting a consistent beneficial effect of L-carnitine on hepatocellular injury across
populations.
As a marker of treatment response, ALT appears to be reliable, and has been closely
correlated to  objectively measured reductions in  liver  fat  using histological  and
imaging methods in NAFLD post-intervention[15,16]. In phase 2 RCTs, ALT continues to
be used as a surrogate marker of disease activity in addition to estimation of fat[17]. The
overall significant reduction in ALT following intervention in the included studies
suggests  a  global  reduction  in  hepatocellular  injury  in  patients  treated  with  L-
carnitine. Indeed, Malaguarnera et al[10] (2010) demonstrated an improvement in all
histological  parameters  in  their  biopsied  NAFLD  cohort  following  L-carnitine
therapy, including steatosis, inflammatory activity and fibrosis. Steatosis reduction
was confirmed using CT with liver attenuation index by Bae et al[11] (2015).
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Figure 4
Figure 4  Meta-analysis of aspartate aminotransferase after intervention.
With respect to translation into clinical practice,  none of the 5 trials evaluated
plasma levels of Trimethylamine-N-Oxide, a metabolite of L-carnitine associated with
increased  risk  of  atherosclerosis.  In  a  population  already  at  high  risk  for
cardiovascular outcomes, the safety profile of L-carnitine supplementation would
require rigorous assessment in this context. However, the evidence base for a direct
adverse link between L-carnitine supplementation and cardiovascular events is to our
knowledge limited. On the contrary, a meta-analysis of 13 placebo-controlled trials
including 3629 patients evaluated the clinical impact of L-carnitine supplementation
in patients with ischaemic heart disease and concluded that carnitine administration
was associated with clinical benefit, including reduced mortality and reduction in
onset  of  cardiac  arrhythmias  and angina[18].  A  recently  published  study  further
concluded that although 24-wk of L-carnitine supplementation increased plasma
Trimethylamine-N-Oxide concentrations, no changes in lipid profile or other serum
biomarkers of atherosclerosis were seen[19].
The evidence collated from studies included in this review forms a compelling
argument for further robust, randomised trial data evaluating mechanisms of action
of L-carnitine on liver and muscle tissue in a NAFLD phenotype, as well as its effect
on validated outcome measures such as liver histology, magnetic resonance imaging
and spectroscopy.  Further,  effects  of  L-carnitine  supplementation  on  metabolic
outcomes in NAFLD require specific attention, for example through utilising gold-
standard measures of liver-specific and whole-body insulin sensitivity such as the
euglycaemic hyperinsulinaemic clamp technique. As a naturally occurring, broadly
applicable,  safe  and cost-effective  agent,  L-carnitine  could overcome traditional
barriers to translation to become routinely available for patients in clinical practice as
an adjunctive treatment for NAFLD.
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Figure 5
Figure 5  Meta-analysis of homeostasis model of insulin resistance measures after intervention.
ARTICLE HIGHLIGHTS
Research background
Non-alcoholic  fatty  liver  disease  (NAFLD)  is  a  leading  cause  of  liver  disease  worldwide,
affecting approximately 25% of the general population. To date, there are no licensed disease-
modifying treatments  to  attenuate global  burden of  NAFLD. A growing body of  evidence
suggests that NAFLD is characterised at a cellular level by impaired mitochondrial fat oxidation.
L-carnitine, a naturally occurring nutrient, is a key mediator of mitochondrial fuel selection and
promotes lipid oxidation. In this article, we synthesise available evidence of a role for L-carnitine
supplementation in the treatment of NAFLD.
Research motivation
L-carnitine has gained traction in recent years as a potential tool for the treatment of metabolic
disorders  including  type  2  diabetes  and  heart  disease.  At  the  nexus  of  glucose  and  lipid
metabolism, L-carnitine promotes mitochondrial lipid oxidation and enhances tissue metabolic
flexibility. It may confer protective effects in NAFLD through these mechanisms. There is a
critical  unmet  need for  broadly applicable,  population based treatment  in  NAFLD,  which
inspired this narrative and quantitative synthesis.
Research objectives
In this study, we aimed to systematically review randomised trials reporting effects of dietary L-
carnitine supplementation on liver biochemistry, liver fat and insulin sensitivity in NAFLD.
Research methods
Ovid  MEDLINE,  Ovid  Embase,  PubMed,  Web  of  Science  and  the  Cochrane  Library  were
searched  from  their  inception  until  April  2019.  Outcome  measures  included  serum
concentrations of alanine and aspartate aminotransferase (ALT and AST), liver fat and insulin
sensitivity assessed by the homeostasis model of insulin resistance (HOMA-IR).  A random
effects  meta-analysis  was  performed  for,  ALT,  AST  and  HOMA-IR  measures  separately.
Between-study heterogeneity was measured using I2 statistics. A protocol for the systematic
review was published a priori in the PROSPERO database (Reference: CRD42018107063).
Research results
Results from the synthesised evidence suggest that L-carnitine is associated with a significant
reduction in serum alanine aminotransferase (ALT), the most commonly used biomarker of
hepatocellular injury. In two robust, high-quality randomised trials, L-carnitine supplementation
reduced  liver  fat  significantly.  Further,  in  subgroup  analysis  of  studies  assessing  insulin
resistance,  L-carnitine  supplementation was associated with a  significant  reduction in  the
HOMA-IR.
Research conclusions
We present an argument for further robust, randomised trial data evaluating mechanisms of
action of L-carnitine on liver and muscle tissue in NAFLD populations. Currently availabile
evidence suggests that as a naturally occurring, broadly applicable and cost-effective agent, L-
carnitine could be an effective tool for patients in clinical practice as an adjunctive treatment for
NAFLD. However, we emphasise that further research using robust and validated endpoints is
required to consolidate existing evidence of benefit.
Research perspectives
Micronutrient  supplementation presents  a  novel  and exciting avenue for  the  treatment  of
population-level diseases, including NAFLD. A broader impact of L-carnitine on metabolic
health (including improved insulin sensitivity) could have implications beyond NAFLD alone
and its effect in other metabolically challenged populations deserves attention. Ultimately,
further well-conducted prospective, randomised data will be required to translate a speculative
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benefit of L-carnitine in NAFLD into the clinical sphere.
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